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Background: Resynthesis of triglycerides in enterocytes of the small intestine plays a critical role in the absorption
of dietary fat. Acyl-CoA:monoacylglycerol acyltransferase-2 (MGAT2) is highly expressed in the small intestine and
catalyzes the synthesis of diacylglycerol from monoacylglycerol and acyl-CoA. To determine the physiological
importance of MGAT2 in metabolic disorders and lipid metabolism in the small intestine, we constructed and
analyzed Mgat2-deficient mice.
Results: In oral fat tolerance test (OFTT), Mgat2-deficient mice absorbed less fat into the circulation. When
maintained on a high-fat diet (HFD), Mgat2-deficient mice were protected from HFD-induced obesity and insulin
resistance. Heterozygote (Mgat2+/−) mice had an intermediate phenotype between Mgat2+/+ and Mgat2−/− and
were partially protected from metabolic disorders. Despite of a decrease in fat absorption in the Mgat2-deficient
mice, lipid levels in the feces and small intestine were comparable among the genotypes. Oxygen consumption
was increased in the Mgat2-deficient mice when maintained on an HFD. A prominent upregulation of the genes
involved in fatty acid oxidation was observed in the duodenum but not in the liver of the Mgat2-deficient mice.
Conclusion: These results suggest that MGAT2 has a pivotal role in lipid metabolism in the small intestine, and the
inhibition of MGAT2 activity may be a promising strategy for the treatment of obesity-related metabolic disorders.
Keywords: Acyl-coenzyme A:monoacylglycerol acyltransferase (MGAT), Obesity, Insulin resistance, Triglyceride,
Enterocyte, Fatty acid oxidationBackground
Intestinal fat absorption involves hydrolysis of dietary
triglycerides to 2-monoacylglycerol and fatty acids in the
lumen by pancreatic lipase [1]. These hydrolysis pro-
ducts are taken up by enterocytes, and triglycerides are
resynthesized through the monoacylglycerol pathway,
which is catalyzed by acyl-CoA:monoacylglycerol acyl-
transferase (MGAT) and acyl-CoA:diacylglycerol acyl-
transferase (DGAT). Another pathway involved in
triglyceride synthesis is the glycerol 3-phosphate pathway,
a de novo pathway that is present in most tissues [2]. In
the small intestinal mucosa, the monoacylglycerol pathway* Correspondence: tsuchida.takuma@mx.mt-pharma.co.jp
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reproduction in any medium, provided the oraccounts for 70–80% of triglyceride resynthesis after a
meal because of the large amount of 2-monoacylglycerol
released from dietary fat [3-5]. The newly formed triglycer-
ides are then incorporated into chylomicrons with other
lipids for secretion into the blood and transport to other
tissues such as the liver and adipose tissue.
MGAT acylates monoacylglycerol to yield diacylgly-
cerol. Three isoforms of MGAT enzymes, MGAT1,
MGAT2, and MGAT3, have been identified thus far
[6-9]. MGAT1 is mainly expressed in the stomach and
kidney and expressed at lower levels in adipose tissue
and the liver, but is absent in the small intestine [9].
MGAT2 and MGAT3 are highly expressed in the small
intestine [6-8,10]. MGAT2 is expressed in both humans
and rodents, and the MGAT3 gene is a pseudogene in
mice [8,11].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protected from metabolic disorders induced by high-fat
feeding and show increased energy expenditure, suggest-
ing that MGAT2 may be a key determinant of fat ab-
sorption and energy metabolism [12]. However, the
exact mechanisms of increased oxygen consumption in
Mgat2-deficient mice are still unknown [12].
In this study, we constructed and analyzed Mgat2-
deficient mice to examine the physiological importance
of MGAT2 in detail, with a focus on lipid metabolism
in the small intestine. We included the heterozygote
(Mgat2+/−) mice because there were limited data on the
phenotype of Mgat2+/− mice [12].
Results
Generation of Mgat2-deficient mice
We generated Mgat2-deficient mice as described in
Methods (Figure 1A). Mgat2−/− mice were viable and
fertile without apparent abnormalities. Mgat2 deficiency
was confirmed by Southern blotting of genomic DNA
(Figure 1B). Gene expression levels of Mgat2 were
reduced in the duodenum of Mgat2+/− mice and un-
detectable in Mgat2−/− mice (Figure 1C). MGAT activity
in the total small intestine was reduced in the Mgat2-
deficient mice (Figure 1D).
Reduced fat absorption in the Mgat2-deficient mice
In oral fat tolerance test (OFTT), plasma triglyceride
levels were transiently increased in Mgat2+/+ but not in
Mgat2−/− mice (Figure 2), indicating inhibition of trigly-
ceride absorption into Mgat2−/− mice circulation.
Reduced body weight gain and adiposity in the
Mgat2-deficient mice
In order to examine the physiological significance of
the inhibition of fat absorption by Mgat2 deficiency on
long-term body weight homeostasis, we challenged the
Mgat2-deficient mice with an ND or HFD. On an ND,
Mgat2+/+, Mgat2+/−, and Mgat2−/− mice showed similar
body weight gains (Figure 3A). In contrast, when main-
tained on an HFD, Mgat2−/− mice exhibited a markedly
reduced rate of body weight gain (Figure 3A). Mgat2−/−
mice showed approximately 26% lower body weight
compared with Mgat2+/+ mice after 10 weeks of HFD
feeding. Mgat2+/− mice had an intermediate phenotype.
Analysis of body composition showed that fat mass was
reduced by approximately 15% in Mgat2+/− and 57% in
Mgat2−/− mice (Figure 3B), with no difference in lean
body mass when maintained on an HFD (Figure 3C).
There was no difference in total food intake based on
body weight (Figure 3D). Therefore, the Mgat2-deficient
mice were protected from HFD-induced obesity inde-
pendent of food intake.Improved insulin sensitivity in the Mgat2-deficient mice
No difference was observed among genotypes in plasma
parameters, including blood glucose, insulin, total choles-
terol, NEFA, and triglycerides in the fed state (Table 1),
and in glucose tolerance (Figure 4A, B) on an ND. When
maintained on an HFD, Mgat2+/+ mice showed an
expected increase in blood glucose, insulin, and total chol-
esterol levels (Table 1) as well as in glucose intolerance
(Figure 4A, B). However, insulin and total cholesterol levels
were significantly reduced in Mgat2+/− and Mgat2−/− mice
(Table 1). Furthermore, Mgat2−/− mice exhibited improve-
ment of glucose tolerance (Figure 4A, B) and increased
insulin sensitivity as assessed by homeostasis model assess-
ment for insulin resistance (HOMA-IR) (Figure 4C). These
data suggested that the Mgat2-deficient mice were pro-
tected from HFD-induced insulin resistance and hyper-
cholesterolemia. Subsequently, we mainly focused on the
HFD-fed groups because no change was observed in the
plasma parameters and body weights of the ND-fed
groups.
Higher oxygen consumption in the Mgat2-deficient mice
Reduced body weight gain without alteration in food in-
take in the Mgat2-deficient mice suggested alterations in
energy metabolism. Oxygen consumption during the
light–dark phase was significantly higher in Mgat2−/−
mice on an HFD (Figure 5).
Lipid levels in feces and the small intestine
We measured lipid levels in feces and the small intestine
to investigate the metabolic fate of unabsorbed triglycer-
ides as a result of Mgat2 deficiency. NEFA levels in feces
was similar among genotypes (Figure 6A), and triglycer-
ide levels in the feces were slightly increased (Figure 6B).
However, fecal outputs of triglycerides were less than 1%
of those contained in an HFD, indicating that the major-
ity of ingested fat exhibited normal uptake by the enter-
ocytes in the Mgat2-deficient mice. Triglyceride levels in
the duodenum, jejunum, and ileum were not different
among genotypes (Figure 6C–E). Histological examin-
ation also showed no difference in the amount of lipid
droplets in the duodenum (data not shown). These
results suggested that in the Mgat2-deficient mice, fat
uptake into the enterocytes was normal but lipids did
not accumulate in the cells.
Expression levels of genes involved in fatty acid oxidation
in the small intestine and the liver
Considering the data obtained from our study, including
that for reduced fat absorption into the circulation, nor-
mal fat uptake in enterocytes, and higher oxygen con-
sumption in the Mgat2-deficient mice, we hypothesized
that unabsorbed lipids were metabolized in the entero-
cytes of the Mgat2-deficient mice. Expression levels of
Figure 1 Generation of Mgat2-deficient mice. (A) Schematic diagram of the derivation of Mgat2-deficient mice by homologous
recombination. (B) Southern blotting of genomic DNA. (C) mRNA levels of Mgat2 in the duodenum. (D) Intestinal MGAT activity. Each bar
represents mean± SEM. n = 3–5 per group. *P< 0.05, **P< 0.01, ***P< 0.001 vs. +/+.
Figure 2 Reduced fat absorption in the Mgat2 deficient mice.
Time course of changes in plasma triglyceride levels after an oral
challenge of Intralipos. Each bar represents mean± SEM. n = 5–6 per
group. *P< 0.05, **P< 0.01 vs. +/+.
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Acox1, Hmgcs2, Acot1, Acot2, Mcad, and Lcad, were sig-
nificantly upregulated in the duodenum of the Mgat2-
deficient mice (Figure 7). The increase of expression
levels of these genes in the liver was not as obvious as
that in the duodenum (Figure 8).
Discussion
In this study, we constructed novel Mgat2-deficient mice
and showed that these mice were protected from HFD-
induced obesity and insulin resistance in accordance
with a recent report by Yen et al. [12]. OFTT showed
that fat absorption into the circulation was significantly
reduced in the Mgat2-deficient mice as a result of inhi-
bition of triglyceride resynthesis in the enterocytes.
Decreased fat absorption may result in protection from
obesity and insulin resistance in mice fed HFD for long-
term. Improvement of insulin sensitivity might be
Figure 3 Reduced body weight gain and adiposity in the Mgat2-deficient mice on an HFD. Time course of changes in body weights (A),
difference in fat mass (B), lean mass (C), and total food intake (D) after 10 weeks of ND or HFD feeding. Each bar represents mean± SEM.
n = 6–15 per group. *P< 0.05, ***P< 0.001 vs. HFD +/+. ###P< 0.001 vs. ND +/+.
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protection against lipotoxicity. Heterozygote (Mgat2+/−)
mice had an intermediate phenotype between Mgat2+/+
and Mgat2−/− and were partially protected from meta-
bolic disorders, indicating a gene dosage-dependent ef-
fect of Mgat2 and feasibility of MGAT2 as a potential
drug target.
Regarding anti-obesity drugs, orlistat is a gastric and
pancreatic lipase inhibitor that reduces dietary fatTable 1 Plasma parameters in the fed state of the Mgat2-defi
ND
Parameter Mgat2+/+ Mgat2+/−
Glucose (mg/dL) 132 ± 4 130 ± 3
Insulin (ng/mL) 1.4 ± 0.2 1.7 ± 0.4
Triglyceride (mg/dL) 114.5 ± 12.5 123.2 ± 12.7
Total cholesterol (mg/dL) 81 ± 5 89 ± 4
NEFA (mEq/L) 0.45 ± 0.03 0.43 ± 0.04
Data are expressed as mean ± SEM. n = 6–15 per group. *P< 0.05, ***P< 0.001 vs. HFabsorption [13]. However, orlistat has mechanism-based
gastrointestinal adverse effects, including fatty and oily
stool, fecal urgency, and fecal incontinence [13]. Fatty
and oily stool was not observed in the Mgat2-deficient
mice in our study. Fecal levels of triglycerides and
NEFAs were comparable among genotypes. Taken to-
gether, the inhibition of MGAT2 may be a safer strategy
than the inhibition of pancreatic lipase for the treatment
of obesity.cient mice
HFD
Mgat2−/− Mgat2+/+ Mgat2+/− Mgat2−/−
135 ± 5 168 ± 6### 168± 5 151 ± 7
2.0 ± 1.0 35.8 ± 10.4## 14.6 ± 3.0* 5.7 ± 1.8*
90.5 ± 5.6 102.7 ± 6.5 119.3 ± 7.4 94.4 ± 7.9
94 ± 7 196 ± 14### 137± 6*** 118 ± 6***
0.36 ± 0.04 0.46 ± 0.02 0.45 ± 0.02 0.46 ± 0.03
D +/+. ##P< 0.01, ###P< 0.001 vs. ND +/+.
Figure 4 Improved glucose tolerance and insulin sensitivity in the Mgat2-deficient mice on an HFD. Time course of changes in blood
glucose (A) and plasma insulin (B) after an oral challenge of 2 g/kg glucose. (C) HOMA-IR was calculated. Each bar represents mean±SEM. n=6–15 per
group. *P< 0.05, **P< 0.01, ***P< 0.001 vs. HFD +/+. #P< 0.05, ###P< 0.001 vs. ND +/+.
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the enterocytes regardless of genotype because less than
1% of triglycerides were detected in the feces of any
genotype. Reduced fat absorption into the circulation
without obvious change in fat uptake into enterocytes
suggested two distinct possibilities of lipid metabolism
in the small intestine. One was the accumulation of
lipids in the cells. However, triglyceride levels in the
duodenum, jejunum, and ileum were comparable, and
histological analysis also showed similar number and size
of lipid droplets in the enterocytes among genotypes.
Another possibility was immediate oxidation of lipids.Figure 5 Increased oxygen consumption in the Mgat2-deficient
mice. Average oxygen consumption during light–dark phase was
measured. Each bar represents mean± SEM. n = 6–15 per group.
***P< 0.001 vs. HFD +/+.The Mgat2-deficient mice exhibited higher oxygen con-
sumption as reported previously [12,14]. Furthermore,
expression levels of genes associated with fatty acid oxi-
dation (Cpt-1a, Acox1, Hmgcs2, Acot1, Acot2, Mcad, and
Lcad) were significantly upregulated in the duodenum of
the Mgat2-deficient mice, whereas in the liver, increase
of the gene expression levels was not as obvious as in
the duodenum. Although the primary function of the
small intestine is the resynthesis of triglycerides and the
secretion of chylomicrons, it has been reported that the
small intestine expresses oxidation-related enzymes,
such as ACOX1 and MCAD, at levels comparable to
those in the liver [15,16] and to a significant extent con-
tributes to the metabolic rate and daily energy expend-
iture [17]. It is possible that activation of fatty acid
oxidation in the enterocytes may lead to higher oxygen
consumption in the Mgat2-deficient mice.
Genes involved in fatty acid oxidation were reported
to have peroxisome proliferator-activated receptor
(PPAR) response elements in their promoter region, and
NEFAs are known to be endogenous ligands of PPARa
[18-22]. Therefore, upregulation of these genes may be
explained by the increased levels of NEFAs, substrates of
MGAT2 enzyme, and endogenous ligands of PPARa, as
a result of the inhibition of triglyceride resynthesis in the
enterocytes. It should be stressed that this hypothesis
requires further investigation including the enzyme ac-
tivity of fatty acid oxidation in the small intestine.
Yen et al. previously reported that the mechanism by
which Mgat2 deficiency triggers oxygen consumption
was unclear and mRNA expression of genes involved in
Figure 6 Lipid levels in the feces and small intestine. Fecal levels of NEFA (A) and triglycerides (B), and triglyceride levels in the duodenum (C),
ileum (D), and jejunum (E) were measured. Each bar represents mean± SEM. n= 3–15 per group. **P< 0.01, vs. HFD +/+. ###P< 0.001 vs. ND +/+.
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tissue showed no differences among genotypes [12]. The
difference in gene expression profiles in the small intestine
between Yen’s study and our results could be explained by
the measurement position used. We analyzed mRNA ex-
pression in the duodenum, whereas the jejunum was used
in the study by Yen et al.
In mice, MGAT2 is mainly expressed in the small intes-
tine. In contrast, in humans, MGAT2 is highly expressed
both in the small intestine and liver[8,23]. It is well known
that the hepatocytes play a key role in lipid metabolism by
accumulating triglycerides and oxidizing fatty acid. Exces-
sive storage and accumulation of lipid droplets into the
hepatocytes result in hepatic steatosis. Therefore, the in-
hibition of MGAT2 activity might lead to lipid oxidation
in the hepatocytes and improvement of fatty liver in
humans.Conclusions
In summary, the Mgat2-deficient mice are protected
from HFD-induced obesity and insulin resistance.
MGAT2 has a pivotal role in lipid metabolism in thesmall intestine, and the inhibition of MGAT2 activity
may be a promising strategy for the treatment of obesity
and type 2 diabetes.Methods
Generation of Mgat2-deficient mice
Mgat2-targeted 129/SvJae embryonic stem cells and,
subsequently, mice carrying this mutation with a target-
ing vector designed to replace exon 1 of Mgat2 with a
neomycin-resistance cassette (Figure 1A) were gener-
ated. Mgat2 deficiency was confirmed by Southern blot-
ting of genomic DNA, which was digested with MfeI
and SoeI using a probe hybridizing to sequences up-
stream of those included in the targeting vector, and by
quantitative PCR. Mgat2−/− and wild-type littermates
were generated by breeding heterozygotes that were first
backcrossed with C57BL/6 J mice. Mice were housed in
a pathogen-free facility. Diets included a normal diet
(ND, CRF-1, Oriental Yeast Co., 3.59 kcal g−1) and a
high-fat diet (HFD, Oriental Yeast Co., 59% cal fat (lard),
5.578 kcal/g). Animals were maintained in a 12/12-h
light–dark cycle. All experiments were performed on
Figure 7 Expression levels of genes involved in fatty acid oxidation in the duodenum of the Mgat2-deficient mice. mRNA levels of genes
involved in fatty acid oxidation were measured in the duodenum. Each bar represents mean± SEM. n = 6–15 per group. *P< 0.05, **P< 0.01,
***P< 0.001 vs. HFD +/+. #P< 0.05, ##P< 0.01, ###P< 0.001 vs. ND +/+.
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use of laboratory animals were reviewed and endorsed
by the Institutional Animal Care and Use Committee of
Mitsubishi Tanabe Pharma Corporation.
MGAT enzyme assays
MGAT activity was determined by measuring the in-
corporation of the [14 C]palmitoyl moiety into triacylgly-
cerol with [14 C]palmitoyl-CoA (ARC, St. Louis, MO)
and 2-monooleoylglycerol. Crude membranes (10 μg) of
the small intestine were used as the enzyme source.
Assays were performed in 200 μl buffer (100 mM Tris–
HCl, pH 7.4, 200 mM sucrose, 5 mM MgCl2, 1.25 mg/ml
BSA) containing 10 μM 2-monooleoylglycerol and 20 μM[14C]palmitoyl-CoA. Reactions were performed for 5 min
at 30°C and the products were extracted with 1 ml of
chloroform:methanol (2:1, v/v). The extracts were dried
and separated by thin layer chromatography with hexane:
diethyl ether:acetic acid (80:20:1, v/v/v). Areas containing
[14C]triacylglycerol were visualized and quantitated using
the FLA3000 fluorescence detection system (Fujifilm,
Tokyo, Japan).
Oral fat tolerance test (OFTT)
Mice were fasted overnight and then 10 ml/kg of Intrali-
pos containing 20 % soybean oil (v/v) (Otsuka, Tokyo,
Japan) was orally administered. Plasma samples were
obtained from the tail vein before and 75, 150, 225, and
Figure 8 Expression levels of genes involved in fatty acid oxidation in the liver of the Mgat2-deficient mice. mRNA levels of genes
involved in fatty acid oxidation were measured in the liver. Each bar represents mean± SEM. n = 6–15 per group. *P< 0.05, **P< 0.01 vs. HFD +/+.
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plasma triglyceride levels.
Long-term feeding studies
Animals were weaned at three weeks of age and main-
tained on an ND or switched to an HFD at seven weeks
of age. They were weighed and their food intake was
monitored. After 10 weeks of HFD feeding, blood sam-
ples in the fed state and feces were collected for 3 days.
After overnight fasting, the mice were killed by whole
blood collection from the abdominal aorta under ether
anesthesia. The small intestine and liver were quickly
removed from each mouse, immediately frozen in liquid
nitrogen, and stored at −80°C for quantitative PCR and
lipid measurements.Determination of body composition
After 10–12 weeks of HFD feeding, the body compo-
sition was analyzed by dual-energy X-ray absorptiometry
with PIXImus2 (GE Healthcare, Tokyo, Japan) under
ether anesthesia.
Determination of plasma parameters
Plasma triglyceride, total cholesterol, and non-esterified
fatty acid (NEFA) levels were determined using an en-
zymatic assay kit (Wako Chemicals, Osaka, Japan).
Blood glucose was determined using commercially avail-
able kits based on the glucose oxidase method (Wako
Chemicals, Osaka, Japan). Plasma insulin was assayed
using an enzyme-linked immunosorbent assay (ELISA)
kit (Morinaga Co. Ltd., Yokohama, Japan).
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An oral glucose tolerance test (OGTT) was performed
after 10 weeks of HFD feeding. Mice were fasted for 3 h
and then 2 g/kg glucose solution was orally administered
at a volume of 10 ml/kg. Blood samples were obtained
from the tail vein before and 15, 30, 60, and 120 min
after the glucose challenge for determination of blood
glucose levels. Plasma samples were obtained before and
15, 30, and 60 min after the glucose challenge for deter-
mination of plasma insulin levels. HOMA-IR was calcu-
lated [24].
Determination of lipid levels in feces and the small
intestine
Fecal lipids were extracted with a 30-fold volume of
chloroform:methanol (2:1, v/v) with vigorous shaking.
Then, a 1/3.75-fold volume of water was added and the
mixture was shaken vigorously. The organic phase was
collected and again a 30-fold volume of chloroform:
methanol (2:1, v/v) was added to the water phase. After
vigorous shaking, the organic phase was collected, and
the combined organic phase was evaporated. The dried
residue was dissolved in isopropanol:Triton X-100 (9:1,
v/v) and measured for triglyceride and NEFA levels
using an enzymatic assay kit. The small intestine was
homogenized in 20-fold volume of saline. Then, lipids
were extracted with a 3.75-fold volume of chloroform:
methanol (2:1, v/v) with vigorous shaking. The organic
phase was collected and evaporated. The dried residue
was dissolved in isopropanol:Triton X-100 (9:1, v/v) and
measured for triglyceride levels using an enzymatic assay
kit.
Determination of oxygen consumption
After 10 weeks of HFD feeding, oxygen consumed by each
mouse was measured using an ARCO-2000 analyzer (Arco
System, Chiba, Japan) every 3 min for a 24-h period.
Histology
Portions of duodenum were fixed in 10 % (v/v) neutral
buffered formalin and embedded in paraffin. Paraffin
sections (3–5 μm thick) were stained with hematoxylin
and eosin and examined under a light microscope.
Quantitative PCR
Total RNA of the duodenum and the liver was extracted
without using DNase. Total RNA was reverse tran-
scribed by TaqMan Reverse Transcriptase Reagents (Ap-
plied Biosystems, Foster City, CA). Real-time PCR was
performed with SYBR Green PCR mix (Applied Biosys-
tems, Foster City, CA) and analyzed with an ABI Prism
7000 Sequence Detection System (Applied Biosystems,
Foster City, CA). The relative expression levels were
compared after normalization to B-actin. The primersused for B-actin and Mgat2 were from QIAGEN (Tokyo,
Japan). The following primer pairs were used (5′ to 3′):
Cpt-1a, forward: AAGCTGTTCAAGATAGCTTG, re-
verse: TGCTGATGACGGCTATGGTGT; Acot1, forward:
GGCTGGGAATGGAGTTTCAT, reverse: GCTATCCAA
GAAAAGTGCCAGG; Acot2, forward: AGTGCCTATGA
AGGACTGAGGA, reverse: GGTAAAGGTGCTTTCTG
CC; Acox1, forward: GGTAAAGGTGCTTTCTGCC, re-
verse: AGATAAACTCCCCAAGATTCAAGAC; Hmgcs2,
forward: TGTCCCCTGAGGAATTCACAGAA, reverse:
AACGAGTGGATGAGATGCATCG; Lcad, forward: CTG
GTTAAGTGATCTCGTGATCGTCG, reverse: CTGGCA




All data were expressed as mean ± SEM. The compari-
son of mean values between two groups was performed
by the Student’s t-test, and the Dunnett’s test was used
for comparing more than two groups. P values of <0.05
were considered statistically significant.
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